within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DE02_Cefpirome;

model Cefpirome
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.3055555555555556e-06,
    adminDuration = 600,
    adminMass = 1000 / 1000000,
    adminCount = 1,
    Vd = 0.014,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.008199999999999999,
    k12 = 2.6666666666666664e-06,
    k21 = 2.6666666666666664e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Cefpirome</td></tr><tr><td>ATC code:</td><td>J01DE02</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>1000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>14.0</td><td>L</td></tr>
    <tr><td>clearance:</td><td>4.7</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cefpirome is a fourth-generation cephalosporin antibiotic that is used to treat severe bacterial infections including those caused by Gram-negative and some Gram-positive organisms. It is administered intravenously, primarily in hospital settings for complicated infections. Although widely used in some regions, in others its clinical use is limited or discontinued.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after single intravenous infusion.</p><h4>References</h4><ol><li><p>Kang, S, et al., &amp; Chang, MJ (2020). Dose Optimization of Cefpirome Based on Population Pharmacokinetics and Target Attainment during Extracorporeal Membrane Oxygenation. <i>Antimicrobial agents and chemotherapy</i> 64(5) –. DOI:<a href=\"https://doi.org/10.1128/AAC.00249-20\">10.1128/AAC.00249-20</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32122899/\">https://pubmed.ncbi.nlm.nih.gov/32122899</a></p></li><li><p>Roos, JF, et al., &amp; Kirkpatrick, CMJ (2007). Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria. <i>Intensive care medicine</i> 33(5) 781–788. DOI:<a href=\"https://doi.org/10.1007/s00134-007-0573-7\">10.1007/s00134-007-0573-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17342515/\">https://pubmed.ncbi.nlm.nih.gov/17342515</a></p></li><li><p>Bulitta, JB, et al., &amp; Sörgel, F (2011). Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers. <i>Antimicrobial agents and chemotherapy</i> 55(6) 2927–2936. DOI:<a href=\"https://doi.org/10.1128/AAC.01484-10\">10.1128/AAC.01484-10</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21402834/\">https://pubmed.ncbi.nlm.nih.gov/21402834</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01DE02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Cefpirome;
